---
title: "Market Insight | KEYMED BIO-B Surges Over 6% Signs Exclusive Licensing Agreement with Belenos Overseas Licensing Two Self-Immunotherapy Drugs"
description: "KEYMED BIO-B is now up more than 6%, as of the deadline for submission, up 5.88% to HKD 33.3, with a turnover of HKD 170.38 million. On the news front, on July 9th, KEYMED announced that it has entere"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/209066654.md"
published_at: "2024-07-17T04:01:03.000Z"
---

# Market Insight | KEYMED BIO-B Surges Over 6% Signs Exclusive Licensing Agreement with Belenos Overseas Licensing Two Self-Immunotherapy Drugs

> KEYMED BIO-B is now up more than 6%, as of the deadline for submission, up 5.88% to HKD 33.3, with a turnover of HKD 170.38 million. On the news front, on July 9th, KEYMED announced that it has entered into a licensing agreement with Belenos Biosciences, granting the latter exclusive rights to research, develop, register, produce, and commercialize the dual-antibody products CM512 and CM536 globally (excluding Greater China). It is reported that as consideration, KEYMED will receive a $15 million upfront payment and near-term payments, while its wholly-owned subsidiary One Bridge Hong Kong will receive approximately 30.01% equity in Belenos; in addition, depending on the development, regulatory, and commercial milestones of the project, KEYMED may also receive up to an additional $170 million

According to the information from the Wise Finance APP, KEYMED BIO-B (02162) is now up more than 6%, as of the time of publication, it has risen by 5.88% to HKD 33.3, with a turnover of HKD 170.38 million.

On the news front, on July 9th, KEYMED BIO announced that it has entered into a licensing agreement with Belenos Biosciences, granting the latter exclusive rights to research, develop, register, produce, and commercialize the dual antibodies CM512 and CM536 globally (excluding Greater China).

It is reported that as consideration, KEYMED BIO will receive a down payment and recent payments totaling USD 15 million, and its wholly-owned subsidiary, One Bridge Hong Kong, will receive approximately 30.01% of Belenos' equity. In addition, depending on the development, regulatory, and commercial milestones of the project, KEYMED BIO is also expected to receive up to an additional USD 170 million in payments

### Related Stocks

- [02162.HK - KEYMED BIO-B](https://longbridge.com/en/quote/02162.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| 亚德诺｜8-K：2026 财年 Q1 营收 31.6 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276224711.md) |
| 康斯托克资源｜10-K：2025 财年营收 22.2 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276369088.md) |
| 康美公司｜10-K：2025 财年营收 13.75 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276145964.md) |
| 缅因州疾病控制与预防中心报告称，缅因州已确认新增 4 例麻疹病例 | 缅因州疾病控制中心：缅因州新增 4 例麻疹确诊病例，目前实验室确认的病例总数达到 5 例 | [Link](https://longbridge.com/en/news/276163950.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.